Aprepitant 125 MG Powder for Oral Suspension [Emend] — RxCUI 1729311
RxNorm drug concept · Semantic branded drug
RxCUI 1729311
Semantic branded drug · SBD
● Current RxNorm concept 5 FDA products
5 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1729311
Official nameAprepitant 125 MG Powder for Oral Suspension [Emend]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEmend 125 MG Powder for Oral Suspension
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)482 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Aprepitant: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Aprepitant is designed to prevent nausea and vomiting before they start — not to treat them once they've kicked in. It's given as part of a combination of anti-nausea medicines, us...
- What exactly is this medicine supposed to do for me?
- Not without a backup plan. Aprepitant can reduce how well hormonal birth control works — that includes the pill, the patch, implants, and some IUDs. This effect can last for a full...
- Can I take my birth control as usual while I'm on this?
🕸️ Concept Web — How Aprepitant 125 MG Powder for Oral Suspension [Em... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Aprepitant 125 MG Powder for Oral Suspension [Emend]
RxCUI 1729311 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Aprepitant
358255IN
-
Aprepitant
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Emend
357280BN
-
Emend
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Aprepitant Powder for Oral Suspension
1729307SCDF -
Aprepitant Oral Powder Product
1729306SCDG -
Aprepitant Oral Product
1157722SCDG -
Aprepitant Powder for Oral Suspension [Emend]
1729309SBDF -
Emend Oral Powder Product
1729310SBDG -
Emend Oral Product
1175305SBDG -
Powder for Oral Suspension
1540456DF -
Oral Powder Product
1294711DFG - +1 more in this family
-
Aprepitant Powder for Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Aprepitant 125 MG Powder for Oral Suspension
1729308SCD -
Aprepitant 125 MG
405797SCDC -
Aprepitant 125 MG [Emend]
576420SBDC
-
Aprepitant 125 MG Powder for Oral Suspension
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Aprepitant 125 MG Powder for Oral Suspension
SCD · 1729308 -
Aprepitant 125 MG
SCDC · 405797 -
Aprepitant Powder for Oral Suspension
SCDF · 1729307 -
Aprepitant Oral Powder Product
SCDG · 1729306 -
Aprepitant Oral Product
SCDG · 1157722
Brand-Name Concepts
-
Aprepitant 125 MG [Emend]
SBDC · 576420 -
Aprepitant Powder for Oral Suspension [Emend]
SBDF · 1729309 -
Emend Oral Powder Product
SBDG · 1729310 -
Emend Oral Product
SBDG · 1175305 -
Emend
BN · 357280
📦 FDA Products & Package NDCs
5 products · 5 package NDCs
5 package NDCs map to RxCUI 1729311 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00006-0461-02 | 2 CAPSULE in 1 DOSE PACK (0006-0461-02) | EMEND | Merck Sharp & Dohme LLC | 2003-03-26 |
| 00006-0461-12 | 2 CAPSULE in 1 DOSE PACK (0006-0461-12) | EMEND | Merck Sharp & Dohme LLC | 2003-03-26 |
| 00006-3066-03 | 1 POUCH in 1 CARTON (0006-3066-03) / 1 POWDER, FOR SUSPENSI... | EMEND | Merck Sharp & Dohme LLC | 2015-12-17 |
| 00006-3862-03 | 1 KIT in 1 DOSE PACK (0006-3862-03) * 1 CAPSULE in 1 CAPSU... | EMEND | Merck Sharp & Dohme LLC | 2003-03-26 |
| 00006-3862-13 | 1 KIT in 1 DOSE PACK (0006-3862-13) * 1 CAPSULE in 1 CAPSU... | EMEND | Merck Sharp & Dohme LLC | 2003-03-26 |
Observed labelers:
Merck Sharp & Dohme LLC (5)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J8501 | Oral aprepitant | 3 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.